UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 76

Sortiert nach

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors

Cancer cell international, 2019-08, Vol.19 (1), p.216-216, Article 216

2019

Volltextzugriff (PDF)

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

BMC cancer, 2020-04, Vol.20 (1), p.328-328, Article 328

2020

Volltextzugriff (PDF)

The role of RICTOR amplification in targeted therapy and drug resistance

Molecular medicine (Cambridge, Mass.), 2020-02, Vol.26 (1), p.20-20, Article 20

2020

Volltextzugriff (PDF)

MET fusions are targetable genomic variants in the treatment of advanced malignancies

Cell communication and signaling, 2024-01, Vol.22 (1), p.20-20, Article 20

2024

Volltextzugriff (PDF)

Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway

Cancer science, 2018-04, Vol.109 (4), p.1088-1100

2018

Volltextzugriff (PDF)

Use tumor suppressor genes as biomarkers for diagnosis of non-small cell lung cancer

Scientific reports, 2021-02, Vol.11 (1), p.3596-3596, Article 3596

2021

Volltextzugriff (PDF)

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

Molecular medicine (Cambridge, Mass.), 2020-08, Vol.26 (1), p.78-78, Article 78

2020

Volltextzugriff (PDF)

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers

Biomedicine & pharmacotherapy, 2020-10, Vol.130, p.110626-110626, Article 110626

2020

Volltextzugriff (PDF)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer

Journal of translational medicine, 2023-02, Vol.21 (1), p.150-150, Article 150

2023

Volltextzugriff (PDF)

Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab

Frontiers in immunology, 2024, Vol.15, p.1387465-1387465

2024

Volltextzugriff (PDF)

Advancement in research and therapy of NF1 mutant malignant tumors

Cancer cell international, 2020-10, Vol.20 (1), p.1-492, Article 492

2020

Volltextzugriff (PDF)

Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis

Cellular oncology (Dordrecht), 2021-10, Vol.44 (5), p.1019-1034

2021

Volltextzugriff (PDF)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

Molecular medicine (Cambridge, Mass.), 2020-07, Vol.26 (1), p.66-66, Article 66

2020

Volltextzugriff (PDF)

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

World journal of surgical oncology, 2024-06, Vol.22 (1), p.159-14, Article 159

2024

Volltextzugriff (PDF)

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma

Translational oncology, 2023-07, Vol.33, p.101685-101685, Article 101685

2023

Volltextzugriff (PDF)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer

Thoracic cancer, 2021-03, Vol.12 (6), p.962-969

2021

Volltextzugriff (PDF)

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing

Frontiers in oncology, 2020-10, Vol.10

2020

Volltextzugriff (PDF)

The role of CD28 in the prognosis of young lung adenocarcinoma patients

BMC cancer, 2020-09, Vol.20 (1), p.910-11, Article 910

2020

Volltextzugriff (PDF)

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study

Translational oncology, 2023-05, Vol.31, p.101657-101657, Article 101657

2023

Volltextzugriff (PDF)

BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Cancer research (Chicago, Ill.), 2012-08, Vol.72 (16), p.4276-4285

2012

Volltextzugriff (PDF)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient

Thoracic cancer, 2020-09, Vol.11 (9), p.2736-2739

2020

Volltextzugriff (PDF)

RIT1 regulates mitosis and promotes proliferation by interacting with SMC3 and PDS5 in hepatocellular carcinoma

Journal of experimental & clinical cancer research, 2023-11, Vol.42 (1), p.1-326, Article 326

2023

Volltextzugriff (PDF)

Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1‐mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2014-04, Vol.59 (4), p.1459-1470

2014

Volltextzugriff (PDF)

Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay

Scientific reports, 2017-11, Vol.7 (1), p.14605-8, Article 14605

2017

Volltextzugriff (PDF)

Isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/m cell cycle arrest and apoptosis

PloS one, 2012-05, Vol.7 (5), p.e36808-e36808

2012

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(74)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

The role of RICTOR amplification in targeted therapy and drug resistance

MET fusions are targetable genomic variants in the treatment of advanced malignancies

Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway

Use tumor suppressor genes as biomarkers for diagnosis of non-small cell lung cancer

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer

Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab

Advancement in research and therapy of NF1 mutant malignant tumors

Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing

The role of CD28 in the prognosis of young lung adenocarcinoma patients

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study

BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient

RIT1 regulates mitosis and promotes proliferation by interacting with SMC3 and PDS5 in hepatocellular carcinoma

Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1‐mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma

Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay

Isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/m cell cycle arrest and apoptosis

Suchergebnisse filtern